TP53 and colonic neoplasm: To examine whether targeting mutant p53 could improve the antitumor effect of ketogenic treatment, a cohort of PDX (P4‐generation of PDX3 in Figure 2C, G+/K−/p53mt) and HT29 (G+/K−/p53mt) colon cancer xenografts were fed a KD together with COTI2 agent, respectively.